Acquisition Opportunity Pharmatek was acquired by Catalent in 2016, indicating access to Catalent's broader distribution and capabilities. This presents an opportunity to position complementary services that fill gaps or extend Catalent’s current HP/C and formulation development offerings.

HP/C Focus Pharmatek offers development and manufacturing support for highly-potent and cytotoxic compounds, suggesting a need for scalable outsourcing partners skilled in advanced containment, regulatory readiness, and specialized analytical methods to support late-stage development and manufacturing.

Mid-market Scale With 51-200 employees and revenue in the 50–100 million range, Pharmatek sits in a mid-market tier that often seeks flexible, project-based partnerships and rapid onboarding for niche formulation, stability testing, and clinical packaging projects.

Clovered CDMO Network As a chemistry development and manufacturing organization offering end-to-end services from discovery to clinic, Pharmatek can be a strategic partner for compound selection, preformulation, formulation development, cGMP manufacturing, and worldwide distribution—a cross-sell across early to late-stage programs.

Global Capabilities Pharmatek provides stability storage and testing, clinical packaging, labeling, and worldwide distribution, indicating potential value in expanding international supply chain services, regulatory support, and compliant serialization to attract multinational clients seeking integrated solutions.